Can the Human Heart Grow New Arteries?

The human heart can and does grow new blood supply routes, though the process is more accurately described as expanding and remodeling tiny pre-existing vessels than building arteries from scratch. When a coronary artery narrows over time, the heart responds by enlarging microscopic arterial connections, called collateral vessels, that already exist between branches of the coronary tree. This remodeling can transform a vessel barely visible on imaging into a functional artery capable of rerouting blood around a blockage. The process is real, clinically meaningful, and varies enormously from person to person.

What Actually Happens When the Heart Builds New Blood Routes

Two distinct processes are at work, and they are often confused. The first, angiogenesis, is the sprouting of entirely new capillaries, the tiniest of blood vessels. Capillaries are good at delivering oxygen over short distances, but they cannot replace a blocked artery. The second process, arteriogenesis, is the one that matters more for restoring meaningful blood flow. Arteriogenesis takes pre-existing but dormant connections between arterial branches and remodels them into larger, muscular vessels that can carry substantial volumes of blood.

Arteriogenesis is driven by physical force, not by oxygen deprivation. When a coronary artery narrows, the pressure downstream drops. Blood gets redirected through nearby collateral vessels, and the increased flow creates shear stress on the vessel walls. That mechanical stimulus activates the cells lining the vessel, triggering a cascade: the endothelial cells swell and begin producing adhesion molecules, white blood cells (particularly monocytes) invade the vessel wall and digest some of the surrounding tissue matrix, and smooth muscle cells and endothelial cells start dividing to enlarge the vessel.

1PubMed. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis)

Angiogenesis, by contrast, is triggered by low oxygen. When heart tissue becomes ischemic, cells switch on a molecular alarm system centered on a protein called hypoxia-inducible factor 1, or HIF-1. HIF-1 drives the production of vascular endothelial growth factor (VEGF) and other signals that coax nearby capillaries to sprout new branches toward the oxygen-starved tissue.

2PubMed. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors Both processes contribute to the heart’s response to blocked arteries, but arteriogenesis is more relevant for restoring the kind of blood flow that can genuinely compensate for a major blockage.3PubMed Central. Arteriogenesis versus angiogenesis: similarities and differences

How Much These Collateral Vessels Vary Between People

One of the most striking findings in this area is just how different the collateral circulation is from one person to the next. Even among people with no detectable coronary artery disease, invasively measured collateral function varies by about tenfold.

4Swiss Medical Weekly. Salient features of the coronary collateral circulation and its clinical relevance Some healthy hearts come equipped with a generous network of dormant arterial connections; others have far fewer. The structural extent of these native collaterals, including both their number and their average diameter, differs substantially between individuals, and no one fully understands why.

This built-in variability helps explain a phenomenon cardiologists have long observed: two patients with the same degree of coronary blockage can have wildly different symptoms and outcomes. One patient might have a complete blockage and barely notice it because robust collaterals have compensated. Another patient with a similar blockage might suffer a major heart attack because their collateral network was sparse to begin with and slow to develop.

Exercise as a Trigger for Collateral Growth

If arteriogenesis is driven by shear stress, then anything that increases blood flow through dormant collateral channels should accelerate the process. Exercise does exactly that. During vigorous physical activity, the heart’s demand for oxygen rises, blood flow increases, and the pressure gradients that push blood through collateral pathways become steeper. Over time, the resulting mechanical stimulus on collateral vessel walls can trigger a remodeling cascade that increases vessel diameter by as much as twentyfold, according to some reports.

5PubMed Central. The Effects of Exercise on Coronary Collateral Circulation: A Review

A randomized trial called EXCITE tested this directly. Patients with stable coronary artery disease were assigned to either a structured exercise program of about ten hours per week or a control group that did not exercise. After four weeks, collateral flow index, a direct measure of how well collateral vessels supply blood to the heart, increased by roughly 40% in both the moderate-intensity and high-intensity exercise groups. The control group showed essentially no change.

6PubMed. Coronary Collateral Growth Induced by Physical Exercise: Results of the Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable Coronary Artery Disease (EXCITE) Trial

Ten hours a week is a lot of exercise, and most people with heart disease are not starting from that baseline. But the finding is still noteworthy: measurable collateral growth happened in just four weeks, suggesting the heart’s remodeling machinery can respond quickly to the right stimulus. The clinical question of how much exercise is enough, and whether lower volumes still produce meaningful collateral improvements, remains an active area of study.

Do Collateral Vessels Actually Save Lives?

Having well-developed collateral circulation is not just an anatomical curiosity. It translates into real survival benefits. A study of patients who had heart attacks involving the front wall of the heart found that one-year mortality was 1% in those with collateral circulation, compared with 8% in those without. The composite of adverse outcomes, including death, repeat heart attacks, and other major events, was also significantly lower in the group with collaterals.

7PubMed Central. Coronary collateral circulation: Effects on outcomes of acute anterior myocardial infarction after primary percutaneous coronary intervention

The mechanism behind this is straightforward. During a heart attack, the tissue downstream of a sudden blockage is starved of blood. Collateral vessels provide an alternate route, keeping at least some of that tissue alive until blood flow can be restored by a procedure or by the body’s own clot-dissolving mechanisms. Research from the early 1990s confirmed this with direct measurements: among patients whose heart attacks were treated with angioplasty, those who had more than half their damaged territory supplied by collateral flow had significantly better heart-wall function one month later than those with less collateral supply.

8PubMed. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction

In practical terms, collateral vessels act as a built-in backup system. They do not eliminate the danger of a heart attack, but they can limit the damage, preserve more heart muscle, and improve the odds of recovery.

When the Process Fails: Diabetes and Impaired Collateral Growth

Not everyone’s heart responds to a narrowing artery by growing adequate collateral supply. Diabetes is one of the clearest negative predictors of collateral vessel development. Research has shown that collateral vessel growth is poorer in patients with diabetes than in those without it.

9PubMed. Effect of diabetes mellitus on formation of coronary collateral vessels

The problem appears to trace back to how immune cells function in diabetic patients. Arteriogenesis depends heavily on monocytes, the white blood cells that invade collateral vessel walls and help remodel them. In people with diabetes, these monocytes have an impaired ability to migrate toward VEGF, one of the key chemical signals that draws them to where new vessel growth is needed. The defect seems to come from faulty signaling within the monocyte itself, not from a lack of the growth factor signal.

10Cardiovascular Research. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications

This is clinically important because people with diabetes are already at elevated risk for coronary artery disease. Having a weaker collateral response on top of more aggressive atherosclerosis is a particularly unfavorable combination. It helps explain why heart attacks in diabetic patients tend to produce larger zones of damage and worse long-term outcomes.

Attempts to Grow Blood Vessels on Demand

The appeal of harnessing this natural process is obvious: if you could stimulate the heart to grow new arteries in patients whose blockages are too diffuse for stenting or bypass surgery, you could help a population that currently has few options. Researchers have been chasing this goal, loosely called “therapeutic angiogenesis,” for over two decades. The results so far are a study in tempered expectations.

Gene therapy trials have delivered growth factors like VEGF directly into the heart muscle, either via viral vectors or as naked DNA. Early small studies were promising. The Kuopio Angiogenesis Trial, for instance, showed improved heart-muscle perfusion in patients who received an adenovirus carrying VEGF, and no major safety concerns emerged even after eight years of follow-up. A more recent phase I/IIa trial using a different VEGF family member, VEGF-D, also showed improved perfusion and angina relief in the treated areas.

11PubMed Central. Progress in Clinical Gene Therapy for Cardiac Disorders

But larger, more rigorous trials have consistently fallen short. The EUROINJECT-One trial, a randomized controlled study of VEGF gene delivery, found no significant improvement in heart-muscle perfusion compared to placebo. The NORTHERN trial similarly failed to show meaningful benefits. The general pattern has been that early smaller studies hint at efficacy, but when tested at larger scale with proper controls, the effects vanish or become too small to matter clinically.

11PubMed Central. Progress in Clinical Gene Therapy for Cardiac Disorders

A newer approach called XC001 uses an adenovirus designed to increase expression of three major VEGF forms at once, rather than just one. A small open-label trial of 32 patients with refractory angina showed some improvement, but without a placebo-controlled comparison, it is difficult to separate real benefit from the substantial placebo effect that plagues angina trials.

12Cardiovascular Research. Gene therapy in cardiac and vascular diseases: a review of approaches to treat genetic and common cardiovascular diseases with novel gene-based therapeutics

One lesson from these trials is that growing arteries is harder than growing capillaries. Delivering VEGF to the heart can sprout new tiny vessels, but the large collateral arteries that actually restore meaningful blood flow require a different set of signals, including mechanical forces that are difficult to replicate with a gene therapy injection alone.

13Cardiovascular Research. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart–gene therapy

Enhanced External Counterpulsation and Mechanical Approaches

Since arteriogenesis responds to shear stress, some researchers have tried to simulate that stimulus externally. Enhanced external counterpulsation, or EECP, uses inflatable cuffs wrapped around the legs that squeeze in rhythm with the heartbeat. During the heart’s resting phase, the cuffs inflate and push blood back toward the heart, increasing coronary blood flow and the shear stress on vessel walls. During the heart’s pumping phase, the cuffs deflate, reducing the workload on the heart.

Modeling studies have shown that EECP improves the flow conditions inside coronary arteries. In arteries with significant narrowing, the treatment reduced the area exposed to unfavorable flow patterns, bringing conditions closer to those seen in healthy vessels.

14PubMed Central. The improvement of the shear stress and oscillatory shear index of coronary arteries during Enhanced External Counterpulsation in patients with coronary heart disease The increased shear stress from EECP also promotes the release of nitric oxide, a molecule that dilates blood vessels and reduces inflammation.

15Scientific Reports. Effect of enhanced external counterpulsation versus individual shear rate therapy on the peripheral artery functions

EECP is already an FDA-cleared treatment for chronic angina. Whether it works primarily by stimulating collateral growth, by improving endothelial function, or through some combination remains debated. But its mechanism aligns with what we know about how arteriogenesis works: increased flow and shear stress driving vessel remodeling.

Lasers, Stem Cells, and Other Experimental Roads

Transmyocardial laser revascularization, or TMR, was developed in the 1990s as a treatment for patients with severe angina who were not candidates for bypass surgery. The idea was to use a laser to drill small channels directly through the heart muscle, creating pathways for blood to reach ischemic tissue. The channels themselves close quickly, but the laser injury triggers an inflammatory response that recruits growth factors and stimulates new vessel formation in the treated area.

16PubMed Central. Transmyocardial laser revascularization17PubMed. Angiogenesis: a possible mechanism underlying the clinical benefits of transmyocardial laser revascularization TMR is still used in select cases, often combined with bypass surgery, but its overall adoption has been limited by inconsistent trial results and the difficulty of proving that any benefit comes from new vessel growth rather than from nerve damage that reduces the sensation of chest pain.

Stem cell therapies represent another frontier. Researchers have explored delivering human mesenchymal stem cells and induced pluripotent stem cells to damaged heart tissue, hoping to stimulate not just new blood vessels but also regeneration of heart muscle itself.

18PubMed Central. Stem Cell Therapies in Cardiovascular Disease Injectable hydrogels are being developed as delivery vehicles that can carry cells and bioactive molecules directly into damaged heart tissue, keeping them in place long enough to promote repair.

19PubMed Central. The Role of Hydrogel in Cardiac Repair and Regeneration for Myocardial Infarction: Recent Advances and Future Perspectives These are still largely experimental, and the gap between animal studies and successful human therapies has proven stubbornly wide.

The Growth Factor Puzzle

One reason therapeutic angiogenesis has been so hard to get right is that blood vessel growth depends on a delicate interplay of multiple growth factors, not just one. Research on developing hearts has shown that capillary formation requires both VEGF and fibroblast growth factor (FGF). But the growth of larger arterioles, the vessels that feed capillary beds, depends more specifically on FGF. When researchers blocked FGF alone, arteriolar growth was severely inhibited. When they blocked VEGF alone, capillaries failed to form but arteriolar length was less affected. When both were blocked together, arteriolar diameter actually increased, suggesting the two factors interact in counterintuitive ways.

20PubMed Central. Role of growth factors in coronary morphogenesis

Adding to this complexity, the HIF-1 pathway that drives the initial angiogenic response to low oxygen doesn’t just turn on VEGF. It activates hundreds of genes involved in vascular reactivity, vessel formation, and the recruitment of bone marrow-derived cells that help build new vessels.

21Cardiovascular Research. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling Delivering one growth factor in isolation, as most early gene therapy trials did, may simply be too crude an approach to replicate the orchestrated response the body naturally produces. The field is gradually moving toward multi-factor strategies and toward understanding how to sequence the signals so that the heart builds vessels of the right type and size.

What Neonatal Hearts and Zebrafish Reveal About Regeneration

The adult human heart’s ability to grow new arteries through arteriogenesis is impressive, but it pales in comparison to what some organisms can do. Zebrafish, for instance, display a high capacity to heal injuries and repair damage to the heart and other organs, including regrowing blood vessels.

22PubMed Central. Apela promotes blood vessel regeneration and remodeling in zebrafish Mammalian hearts, by contrast, lose most of their regenerative potential early in life. A landmark study in mice showed that at one day old, a neonatal heart can regenerate after having a piece surgically removed, including restoring functional tissue and blood supply. By seven days of age, that capacity is gone.

23PubMed Central. Transient regenerative potential of the neonatal mouse heart

Spatial mapping of gene activity in neonatal mouse hearts has begun to reveal what changes during that critical first week. The cardiac scar that forms after injury transitions from a tissue-building, proliferative state to a secretory one, essentially switching from active repair to passive scarring. This transition coincides with the loss of regenerative ability.

24PubMed Central. Characterizing Neonatal Heart Maturation, Regeneration, and Scar Resolution Using Spatial Transcriptomics

Understanding what silences regeneration in postnatal mammals is one of the most active questions in cardiac biology. If researchers can figure out how to reactivate even part of that neonatal program in adult hearts, the implications would go far beyond growing new collateral arteries. It could mean regenerating dead heart muscle itself, something the adult heart currently cannot do in any meaningful way. For now, though, the adult heart’s best trick remains arteriogenesis: not true regeneration, but a resourceful improvisation that turns dormant pathways into functional lifelines.